Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTR5A | P47898 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HK1 | P19367 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GALK1 | P51570 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Charcoal, Activated SCHEMBL31304029 | 0.98 | ALOX15 (0.39) | ALOX15HSD17B10HTR5AGAANPSR1 | |
| SCHEMBL31713015 | 0.93 | ALOX15 (0.39) | ALOX15HSD17B10HTR5AGAANPSR1 | |
| SCHEMBL56377 | 0.85 | — | — | |
| SCHEMBL29650387 | 0.85 | — | — | |
| Cyanide SCHEMBL15661517 | 0.79 | ALOX15 (0.39) | ALOX15HSD17B10HTR5AGAANPSR1 | |
| SCHEMBL31712973 | 0.77 | HTR2C (0.44) | ALOX15HSD17B10GAANPC1MEN1 | |
| SCHEMBL5474126 | 0.74 | ALOX15 (0.48) | ALOX15HSD17B10HTR5AGAANPSR1 | |
| SCHEMBL30390513 | 0.71 | — | — | |
| SCHEMBL29374426 | 0.70 | PNMT (0.50) | ALOX15HSD17B10PNMTCD44MAOB | |
| SCHEMBL214465 | 0.70 | PNMT (0.50) | ALOX15HSD17B10PNMTCD44MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250338712-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | SAMSUNG DISPLAY CO LTD (KR) | 2025-10-30 | — | — | US | claimed |
| EP-2602242-A1 | PROCESS FOR PREPARING COMPOUND BY NOVEL SANDMEYER-LIKE REACTION USING NITROXIDE RADICAL COMPOUND AS REACTION CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-12 | — | — | EP | claimed |
| US-20130144061-A1 | PROCESS FOR PREPARING A COMPOUND BY A NOVEL SANDMEYER-LIKE REACTION USING A NITROXIDE RADICAL COMPOUND AS A REACTION CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-06 | — | — | US | claimed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | claimed |
| JP-2007504176-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1663993-A1 | GUANIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023781-A1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-03-17 | — | — | WO | claimed |
| US-20250338712-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | SAMSUNG DISPLAY CO LTD (KR) | 2025-10-30 | — | — | US | disclosed |
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-05-12 | — | — | US | disclosed |
| US-20180362475-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-12-20 | — | — | US | disclosed |
| EP-3217982-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016075137-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-05-19 | — | — | WO | disclosed |
| US-9233980-B2 | Process for preparing a compound by a novel sandmeyer-like reaction using a nitroxide radical compound as a reaction catalyst | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-12 | — | — | US | disclosed |
| EP-1858883-A2 | HETEROCYCLIC N-OXIDES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | Sentinel Oncology Limited (GB) | 2007-11-28 | — | — | EP | disclosed |
| EP-1846392-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | Sentinel Oncology Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
| WO-2006131835-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006120573-A2 | HETEROCYCLIC N-OXIDES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
| EP-1663993-A1 | GUANIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023781-A1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | AIFM2, BAD, AIFM1 | ALOX15 84/4885HSD17B10 1082/4885HTR5A 1289/4885 |
| US-20070123510-A1 | Guanidine derivatives | NPFFR1, NPFFR2, OGFR | ALOX15 3362/4885HSD17B10 4313/4885HTR5A 134/4885 |
| US-20130144061-A1 | PROCESS FOR PREPARING A COMPOUND BY A NOVEL SANDMEYER-LIKE REACTION USING A NITROXIDE RADICAL COMPOUND AS A REACTION CATALYST | TYR, NOX5, NOXO1 | ALOX15 1235/4885HSD17B10 2894/4885HTR5A 2242/4885 |
| US-20180362475-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | AIFM2, BAD, AIFM1 | ALOX15 84/4885HSD17B10 1082/4885HTR5A 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.